Loading...
Please wait, while we are loading the content...
Similar Documents
Incremental validity of the Minnesota Multiphasic Personality Inventory -2 (MMPI-2) relative to the Beck Depression Inventory
| Content Provider | Semantic Scholar |
|---|---|
| Author | Serrano, Daniela |
| Copyright Year | 2016 |
| Abstract | Background: Psychiatric comorbidities are extremely common among patients with heterogeneous neurological disorders, including seizure disorders. Prevalence rates range from 20% to 50%, with depression being the most common, particularly in patients with epilepsy. Despite the high comorbidity, depression is often under-recognized in patients with neurological conditions. To reduce the under-recognition of depression, mood screening should be part of the routine medical and neuropsychological evaluation. Sensitive screening tools that allow detection of psychopathology as well as of response biases should be used for assessment to aid diagnostic accuracy, given medical patients may under-report or over-report their symptoms for multiple reasons. The aim of this study was to determine the incremental validity of the Minnesota Multiphasic Personality Inventory -2 (MMPI-2), relative to the Beck Depression Inventory Second Edition (BDIII) in the detection of depression amongst neurological patients. An additional aim was to determine whether over-reporting and under-reporting as measured by the MMPI-2 validity scales, predicted BDI-II scores. Method: Participants were divided into two subsamples for exploratory analysis, a heterogeneous neurosciences sample and a seizure disorders sample. All participants completed the MMPI-2 and BDI-II when seen for neuropsychological assessment at the Neuropsychology Service of St. Vincent‟s Hospital, Melbourne, Australia. Depression rates as measured by each instrument were compared and the prevalence of over-reporting and under-reporting by subsample was also explored. Results: A total of 31.8% participants were classified as depressed by both, the BDI-II and the MMPI-2 Scale 2 and 38.2% participants were classified as not depressed by both tools. However, the BDI-II missed a total of 24.4% cases of depression detected by Scale 2, INCREMENTAL VALIDITY OF THE MMPI-2 RELATIVE TO THE BDI-II 3 whereas Scale 2 only missed 5.7% of depressed cases detected by the BDI-II. Depression rates did not vary significantly by subsample, but more severe depressive symptoms were reported by participants in the heterogeneous neurosciences sample. Over-reporting and under-reporting rates were similar for both subsamples. Multiple linear regression results indicted MMPI-2 depression (Scale 2) and over-reporting of symptoms (scale Fb) predicted BDI-II scores in both subsamples. Under-reporting of symptoms (scales L) was also found to be a significant predictor of BDI-II scores in the seizure disorders sample. Conclusions: The MMPI-2 Scale 2 appears to be a more sensitive screening tool than the BDI-II in the detection of depression amongst patients with heterogeneous neurological conditions. If only the BDI-II is used to screen for depression, there is a high risk of committing misclassification errors as BDI-II scores are influenced by over-reporting and underreporting of symptoms. INCREMENTAL VALIDITY OF THE MMPI-2 RELATIVE TO THE BDI-II 4 |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | http://repositorio.educacionsuperior.gob.ec/bitstream/28000/2121/1/T-SENESCYT-01248.pdf |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |
